These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31260659)

  • 1. Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons.
    Vargas-Franco JW; Castaneda B; Gama A; Mueller CG; Heymann D; Rédini F; Lézot F
    Biochem Pharmacol; 2019 Oct; 168():133-148. PubMed ID: 31260659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid.
    Lézot F; Chesneau J; Navet B; Gobin B; Amiaud J; Choi Y; Yagita H; Castaneda B; Berdal A; Mueller CG; Rédini F; Heymann D
    Bone; 2015 Apr; 73():51-9. PubMed ID: 25532478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
    Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies.
    Lézot F; Chesneau J; Battaglia S; Brion R; Castaneda B; Farges JC; Heymann D; Rédini F
    Bone; 2014 Nov; 68():146-52. PubMed ID: 25193159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
    Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
    PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.
    Koch FP; Merkel C; Ziebart T; Smeets R; Walter C; Al-Nawas B
    Clin Oral Investig; 2012 Feb; 16(1):79-86. PubMed ID: 20938793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice.
    Sheng ZF; Xu K; Ma YL; Liu JH; Dai RC; Zhang YH; Jiang YB; Liao EY
    Osteoporos Int; 2009 Jan; 20(1):151-9. PubMed ID: 18496637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
    Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
    Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanical loading influences the effects of bisphosphonates on human periodontal ligament fibroblasts.
    Jacobs C; Walter C; Ziebart T; Dirks I; Schramm S; Grimm S; Krieger E; Wehrbein H
    Clin Oral Investig; 2015 Apr; 19(3):699-708. PubMed ID: 25055746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Exposure to ZnO Nanoparticles Disrupt the Structure of Bone in Young Rats via the OPG/RANK/RANKL/IGF-1 Pathway.
    Xu X; Tang Y; Lang Y; Liu Y; Cheng W; Xu H; Liu Y
    Int J Nanomedicine; 2020; 15():9657-9668. PubMed ID: 33299310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.
    Li M; Xu D
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17187-17194. PubMed ID: 32636266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
    Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
    Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
    Stolina M; Dwyer D; Ominsky MS; Corbin T; Van G; Bolon B; Sarosi I; McCabe J; Zack DJ; Kostenuik P
    J Immunol; 2007 Dec; 179(11):7497-505. PubMed ID: 18025194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-RANKL treatment improves screw fixation in cancellous bone in rats.
    Bernhardsson M; Sandberg O; Aspenberg P
    Injury; 2015; 46(6):990-5. PubMed ID: 25744169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactation induces increases in the RANK/RANKL/OPG system in maxillary bone.
    Macari S; Sharma LA; Wyatt A; da Silva JM; Dias GJ; Silva TA; Szawka RE; Grattan DR
    Bone; 2018 May; 110():160-169. PubMed ID: 29382610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
    Dela Cruz A; Grynpas MD; Mitchell J
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heamatococcus pluvialis ameliorates bone loss in experimentally-induced osteoporosis in rats via the regulation of OPG/RANKL pathway.
    El-Baz FK; Saleh DO; Abdel Jaleel GA; Hussein RA; Hassan A
    Biomed Pharmacother; 2019 Aug; 116():109017. PubMed ID: 31158803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice.
    Alam I; Alkhouli M; Gerard-O'Riley RL; Wright WB; Acton D; Gray AK; Patel B; Reilly AM; Lim KE; Robling AG; Econs MJ
    Endocrinology; 2016 Feb; 157(2):722-36. PubMed ID: 26584014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of chronic zoledronate usage on the jaw and long bones evaluated using RANKL and osteoprotegerin levels in an animal model.
    Çankaya M; Cizmeci Şenel F; Kadioglu Duman M; Muci E; Dayisoylu EH; Balaban F
    Int J Oral Maxillofac Surg; 2013 Sep; 42(9):1134-9. PubMed ID: 23522850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
    Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
    Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.